Thermi

Thermi Launches New Platforms for Clinical Education

Thermi Introduces New Training Initiatives for Physicians

In an effort to help its customers achieve optimal outcomes and spur innovation for future product development, Thermi, developer of radiofrequency-based devices for skin tightening and fat reduction, has launched two new clinical training initiatives. In 2018, the company is introducing 36 National Centers of Excellence in which new, existing and prospective customers can observe and work with experienced Thermi providers.

Thermi Co-Founder Joins Ideal Implant Board of Directors

Ideal Implant adds new talent.

Ideal Implant, founded in 2006 to develop, manufacture and market the saline IDEAL IMPLANT Structured Breast Implant has appointed Paul Herchman, co-founder and former CEO of ThermiGen, to its board of directors. He will act as a consultant in corporate development. Current board member Kevin Morano will assume the role of chief financial officer, continuing to lead the company's financial strategy, and Gabe Walters has been promoted from national sales director to vice president of U.S. sales.

Almirall Acquires Thermi

Barcelona-based pharmaceutical company Almirall has announced the completion of the acquisition of 100% of the share capital of ThermiGen LLC after all closing conditions have been satisfied. Under the terms of the agreement, Almirall has acquired ThermiGen for an enterprise value of $82 million—this represents the definitive entry of Almirall into the aesthetics market.

Thermi Moves Headquarters to Texas

Aesthetics technology company Thermi (formerly ThermiAesthetics) has moved its company headquarters to a larger, 14,000-square-foot facility in Irving, Texas, to accommodate the company’s continued worldwide expansion. The new location houses the company’s corporate departments, including research and development, warehousing and shipping. The facility also includes a training center where physicians can meet and collaborate with colleagues and Thermi respresentatives.